About Remidio
Remidio is a Healthcare company based in Bengaluru (India) founded in 2009 by Anand Sivaraman. AI-powered portable solutions for ophthalmic screening and diagnosis are developed. Remidio has raised $25.01 million across 10 funding rounds from investors including Sun Pharma, KITVEN and Montane Ventures. The company has 135 employees. Remidio was last valued at $67.5 million in February 2023. Its chief executive, as recorded, is Anand Sivaraman. Its Indian entity Remidio Innovative Solutions Private Limited reported revenue of ₹55.31 Cr. Remidio offers products and services including Fundus On Phone, Portable Slit Lamp, Medios DR, and Instaref R20. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Imaging. Its competitors include Forus Health and Cyclops MedTech; 2 of its 2 listed competitors have raised funding.
Company details
Remidio was founded in 2009 in Bengaluru, India, focusing on the healthcare sector with an emphasis on ophthalmology. AI and telemedicine are integrated into portable digital devices for eye testing and diagnosis. Products such as Fundus on Phone (FOP-NM), Portable Slit Lamp (PSL-D20), Instaref R20, Anterior Imaging Module (AIM), and Microscope Recording Device (MRD) are offered to support screening operations.
- Headquarters Bengaluru, India
- Employees 135
- Founders Anand Sivaraman
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website remidio.com/en-in
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Remidio Innovative Solutions Private Limited
- Date of Incorporation 19 Nov, 2009
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹55.31 Cr
FY 2025 · +14% YoY
- Net Loss-₹17.00 Cr
FY 2025 · -31% margin
- EBITDA-₹10.79 Cr
FY 2025 · -20% margin
- Total Equity Funding$25.01M (USD)
in 10 rounds
- Latest Funding Round$18.09M (USD), Series B
Feb 2023
- InvestorsSun Pharma
& 26 more
- Employee Count135
Associated legal entities of Remidio
Remidio operates through Remidio Innovative Solutions Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Remidio Innovative Solutions Private Limited CIN U73100KA2009PTC051546 | Active | 19 Nov 2009 | Bangalore, Karnataka | ₹55.3 Cr | 135 | 4 | View details |
Products & Services of Remidio
Remidio offers a comprehensive portfolio of products and services, including Fundus On Phone, Portable Slit Lamp, Medios DR, and Instaref R20.
Device for non-mydriatic fundus imaging and eye health monitoring.
Handheld device for slit imaging in ophthalmic examinations.
AI tool for screening diabetic retinopathy offline.
Aberrometer for eye measurements and diagnostics.
Apps and channels of Remidio
its YouTube channel Remidio has 1.59K subscribers and 30 videos.
Videos from Remidio
The most watched videos on Remidio's YouTube channel, Remidio (1.59K subscribers). Click a video to play it here.
More on Remidio.
Funding Insights of Remidio
Remidio has successfully raised a total of $25.01M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $18.09 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.01M
- Total Rounds 10
- Last Round Series B — $18.09M
- First Round $125,300
(May 2015)
- Investors Count 27
All 10 funding rounds of Remidio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $18.09M | Series B | $67.5M | Sun Pharma | – |
| Jun 2021 | $2.86M | Series B | $29.96M | Anand Sivaraman, Zubin Daruwalla | |
| Nov 2020 | $10,000 | Grant | – | – | |
| Dec 2019 | $1.05M | Series B | $••••• | Montane Ventures | |
| May 2018 | $1.33M | Series B | $••••• | Montane Ventures | – |
| Aug 2017 | $856,765 | Series B | $••••• | KITVEN | – |
| Jan 2017 | $150,895 | Series B | $••••• | Deepak Darda | |
| Jan 2016 | Series B | – | – | ||
| Nov 2015 | $542,430 | Angel Round | $••••• | Dhanesh Shah, Sonal Shah | – |
| May 2015 | $125,300 | Seed | $••••• | Cipher-Plexus |
| Date | Valuation | Stage |
|---|---|---|
| Feb 2023 | $67.5M | •••••••• |
| Jun 2021 | $29.96M | •••••••• |
| Dec 2019 | $••••• | •••••••• |
| May 2018 | $••••• | •••••••• |
| Aug 2017 | $••••• | •••••••• |
| Jan 2017 | $••••• | •••••••• |
| Nov 2015 | $••••• | •••••••• |
| May 2015 | $••••• | •••••••• |
Full valuation and stage history of Remidio
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $67.5M (Feb 2023). 27 investors in total: 10 institutional and 17 angel.
Investors in Remidio
Remidio has secured backing from 27 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Sun Pharma, KITVEN and Montane Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology startups are funded by Pureland Group through venture capital. | purelandgroup.co | Singapore, Singapore | ||
Venture capital fund partnering with entrepreneurs in technology and health sectors. | 2015 | montaneventures.com | Mumbai, India | |
Deep tech investments in AI and 4th industrial revolution technologies across Europe. | 2016 | boundaryholding.com | ||
Acceleration of medical device, digital health, and diagnostic companies is facilitated worldwide. | medtechinnovator.org | |||
Venture capital fund backed by government financial institutions focused on early and growth stage startups | 1999 | kitven.in | Bengaluru, India | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India | |
Business consulting and marketing services are provided to clients. | Singapore, Singapore | |||
Corporate and M&A advisory services are offered across multiple sectors. | cipherplexus.in | Mumbai, India |
Investor details for Remidio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Remidio Innovative Solutions Private Limited (Remidio)
Remidio Innovative Solutions Private Limited is the primary company behind Remidio. The board of Remidio Innovative Solutions Private Limited currently have 4 directors; the longest-serving is Anand Sivaraman, appointed in 2010. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anand Sivaraman DIN 03307431 | Managing Director | 04 Dec 2010 | 15 yrs 11 mo | Remidio Innovative Solutions Private Limited |
| Pajir Vishwanath Rajesh Rai DIN 03284892 | Nominee Director | 30 May 2018 | 8 yrs 5 mo | Remidio Innovative Solutions Private Limited |
| Wilson Dsouza DIN 03307428 | Nominee Director | 22 Mar 2023 | 3 yrs 7 mo | Remidio Innovative Solutions Private Limited |
| Ziyu Wang DIN 08914403 | Nominee Director | 24 Jul 2023 | 3 yrs 3 mo | Remidio Innovative Solutions Private Limited |
People of Remidio
48 people are tracked at Remidio (19 in leadership, 29 in team); the tracked headcount is 135.
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO | Leadership | |
Sundeep Agarwal | Senior Vice President | Leadership |
Saurabh Darda | Vice President International Business Development | Leadership |
Chirag Gogri | General Manager Marketing | Leadership |
Erik Hafkey | Chief Commercial Officer USA | Leadership |
Sudhakar VJA | Vice President-Govt Business | Leadership |
| COO- Remidio India | Leadership | |
Hardik Desai | Vice President of Sales & Marketing | Leadership |
Anoop T A | Head - R&d Mechanical Systems | Leadership |
Ronnie Dutta | VP - Sales And Marketing . Pharma Business Development | Leadership |
Vighnesh M J | Head Of Training | Leadership |
Krishna P V | VP Engineering | Leadership |
Mahesh Venkitachelam | Head of Software | Leadership |
Ashish Lal | Vice President of Products | Leadership |
Anshu Tiwari | Head Legal Company Secretary | Leadership |
Shonraj Ballae Ganeshrao | Head Of Clinical Research | Leadership |
Siva G | Head - Projects, NPD | Leadership |
Vibu Surendran | Head Of Design | Leadership |
Bhargav Sosale | VP | Leadership |
Hardik Parmar | Field Services Engineer | Team |
28 more people are available in the full profile.
Complete people profiles for Remidio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Remidio
Figures of Remidio Innovative Solutions Private Limited, the primary company behind Remidio, for FY 2025. Revenue was ₹55.31 Cr (+14% year on year). Net loss was -₹17.00 Cr (-31% margin). EBITDA was -₹10.79 Cr (-20% margin). Revenue has grown at a compounded annual rate of +25% over three years and +23% over five years.
- ₹55.31 CrRevenue · FY 2025 · +14% YoY
- -₹17.00 CrNet loss · -31% margin
- -₹10.79 CrEBITDA · -20% margin
- ₹4.69 CrPaid-up capital
- 135Employees (provident fund records)
- +25%Revenue CAGR, 3 years
- +23%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Remidio Innovative Solutions Private Limited are on its company page.
Detailed financial statements for Remidio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Remidio
4 dated milestones of Remidio across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Remidio is founded.
- Funding First funding round of $125K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $18.1M.
Competitors of Remidio
Remidio has 2 listed competitors in our database, 2 of them funded. They include Forus Health and Cyclops MedTech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| forushealth.com | 2010 | Bengaluru, India | $18.12M | 171 | Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | |
| cyclopsmedtech.com | 2015 | Bengaluru, India | $1.25M | 15 | Provider of an AI and VR-based eye tracking solution for eye balancing and testing |
Detailed competitors of Remidio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Remidio
The website of Remidio (remidio.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 51.7% vs previous month
Websites whose visitors overlap most with Remidio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
retinamd.com | retinamd.com | 100% | #4,255,378 | – | |
fevr.net | fevr.net | 63% | – | ||
| retinaconsultations.com | 62% | View details | |||
| retinaresearchfnd.org | 62% | #5,748,679 | View details | ||
eyeinjury.com | eyeinjury.com | 62% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Remidio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Remidio
Complete news archive for Remidio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remidio
Remidio was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Remidio is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Anand Sivaraman is the CEO of Remidio, as recorded in our data. They have also founded this company.
Remidio is a funded company, having raised a total of $25.01M across 10 funding rounds to date. The company's 1st funding round was a Seed of $125.3K, raised on May 2015.
Remidio has 135 employees.
The primary company behind Remidio, Remidio Innovative Solutions Private Limited, reported revenue of ₹55.31 Cr for FY 2025, up 14% year on year.
Remidio was founded in 2009 in Bengaluru, India, focusing on the healthcare sector with an emphasis on ophthalmology. AI and telemedicine are integrated into portable digital devices for eye testing and diagnosis. Products such as Fundus on Phone (FOP-NM), Portable Slit Lamp (PSL-D20), Instaref R20, Anterior Imaging Module (AIM), and Microscope Recording Device (MRD) are offered to support screening operations.
Remidio's top competitors include Forus Health and Cyclops MedTech.
Remidio offers Fundus On Phone, Portable Slit Lamp, Medios DR, and Instaref R20.
Remidio has 27 investors. Key investors include Sun Pharma, KITVEN, Montane Ventures, Pureland Group, and Yongfah Capital.
The valuation of Remidio is $67.5M as of Feb 2023.
Remidio operates through Remidio Innovative Solutions Private Limited.